{"name":"Patrick Ott, MD, PhD","slug":"patrick-ott-md-phd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxQVzgwR1dXdGJHRG5zeW5xSVotUXpjZWtmTFpmMDg2Uk9UUjVMMG4yY1JXdlgwMDVoRXlnRThmMkgtTzZwNUk3YWFwbjg5cGNDODFfV19ON2pkZjFremU0YXU4bUtjWDBBSC1YWmNlaEZaQ3UwRkdDcVFPTFpLekU2RGtQZm1TTlJaY3BJYzNoempDZ0h6aExwTHp0R0NpS3BVbHB3?oc=5","date":"2026-01-20","type":"pipeline","source":"Dana-Farber Cancer Institute","summary":"Ten Cancer-Related Breakthroughs Giving Us Hope in 2026 - Dana-Farber Cancer Institute","headline":"Ten Cancer-Related Breakthroughs Giving Us Hope in 2026 - Dana","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMie0FVX3lxTE04bHBsU3dET05PUHZwWkVUbzEzZHdUMXAxNExzakVWSXIteEFBdC1paHFsY2xEZzAyRWZlVWtja0xLMFl3UWp5QXQ2UVAzLUk0RHVhMWkxdEd0UDdBVVNiZlBOUXNqMGpzaEVMb000U1VaNlZEZmRhWXpWbw?oc=5","date":"2019-01-28","type":"trial","source":"Wiley","summary":"A phase 2 study of glembatumumab vedotin, an antibody-drug conjugate targeting glycoprotein NMB, in patients with advanced melanoma - Wiley","headline":"A phase 2 study of glembatumumab vedotin, an antibody-drug conjugate targeting glycoprotein NMB, in patients with advanc","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}